The market correctly sees biology's potential but often misunderstands its timeline. Even with AI, biology is fundamentally harder and slower than software. Daniel Fero warns this mismatch in "tempo" expectations leads to over-funding hype cycles while under-funding foundational companies that are simply moving at the pace required for rigorous biological R&D.

Unlike tech investing, where a single power-law outlier can return the entire fund, biotech wins are smaller in magnitude. This dynamic forces biotech VCs to prioritize a higher success rate across their portfolio rather than solely hunting for one massive unicorn.

Even with big wins, a venture portfolio can fail if not constructed properly. The relative size of your investments is often more critical than picking individual winners, as correctly sized successful investments must be large enough to overcome the inevitable losers in the portfolio.

Top growth investors deliberately allocate more of their diligence effort to understanding and underwriting massive upside scenarios (10x+ returns) rather than concentrating on mitigating potential downside. The power-law nature of venture returns makes this a rational focus for generating exceptional performance.

In venture capital, the potential return from a single massive winner (1000x) is so asymmetric that it dwarfs the cost of multiple failures (1x loss). This reality dictates that the primary focus should be on identifying and capturing huge winners, making the failure to invest in one a far greater error than investing in a company that goes to zero.

Emerging VCs miscalculate risk by chasing a "safer" 3x return. The venture model demands asymmetric bets; a 10% chance at a 100x return is superior to a risky 3x, as both could result in a zero. Venture is not private equity.

Venrock partner Brian Roberts states that a 2-3x return, often considered good in other sectors, is poor in biotech. The decade-long timelines and extremely high failure rates necessitate massive "70x" outlier wins to make a fund's investment model viable.

While biotech cannot easily replicate tech's rapid iteration cycles due to high costs and long feedback loops, it can adopt the capital efficiency model of tech seed investing. The strategy is to kill flawed projects quickly and cheaply, ensuring that when you lose, you lose small.

VC outcomes aren't a bell curve; a tiny fraction of investments deliver exponential returns covering all losses. This 'power law' dynamic means VCs must hunt for massive outliers, not just 'good' companies. Thiel only invests in startups with the potential to return his whole fund.